2-methoxy-5-p-tolyl-pyrimidine | 27956-12-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-methoxy-5-p-tolyl-pyrimidine
• 英文别名: 2-Methoxy-5-p-tolylpyrimidin；2-Methoxy-5-(4-methylphenyl)pyrimidine；2-methoxy-5-(4-methylphenyl)pyrimidine
• CAS: 27956-12-3
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: HRAKEZCURWMLHT-UHFFFAOYSA-N

物化性质

• 熔点：
  80-81 °C
• 沸点：
  355.9±45.0 °C(Predicted)
• 密度：
  1.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  甲醇 、 2-氯-5-(对甲苯基)嘧啶 在 sodium 作用下， 反应 0.17h， 以98%的产率得到2-methoxy-5-p-tolyl-pyrimidine
  参考文献：
  名称：

  简单的无微波辅助的无配体铃木交叉偶联：卤代嘧啶部分的功能化

  摘要：

  描述了用于铃木偶联的有利的无配体方案。合成过程需要微波辐射以缩短反应时间，并使用硅胶柱进行纯化。选择了在药物化学中令人感兴趣的支架二卤代嘧啶结构作为测试化合物。

  DOI：

  10.1002/jhet.5570450420

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20130281433A1

  公开（公告）日：2013-10-24

  Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

  本文披露的化合物包括公式I′的化合物及其盐。还提供了包含本文披露的化合物的药物组合物、制备本文披露的化合物的方法、用于制备本文披露的化合物的中间体以及使用本文披露的化合物治疗HIV感染的治疗方法。
• Novel compounds that are ERK inhibitors
  申请人：Deng Yongqi

  公开号：US20070232610A1

  公开（公告）日：2007-10-04

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明涉及一种化学式1.0的ERK抑制剂，以及其药学上可接受的盐和溶剂。其中，Q为一个哌啶或哌嗪环，可以有一个桥或一个融合环。哌啶环中可以在环中有一个双键。所有其他取代基如定义所述。本发明还涉及使用化合物1.0治疗癌症的方法。
• LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Umemura Eijirou

  公开号：US20100184746A1

  公开（公告）日：2010-07-22

  An objective of the present invention is to provide compounds of formula (I) or their pharmacologically acceptable salts or solvates wherein A represents aryl while R 1 represents a five- or six-membered monocyclic heterocyclic group, or A represents a four- to six-membered monocyclic heterocyclic group while R 1 represents aryl or a five- or six-membered monocyclic heterocyclic group; R 2 represents a hydrogen atom or C 1-6 alkyl; R 3 represents C 1-6 alkyl or C 3-6 cycloalkyl-C 1-4 alkyl; R 4 , R 5 , and R 6 represent a hydrogen atom; R 7 represents C 1-6 alkyl; and m is 1 to 3. The compounds are novel lincosamide derivatives that have a potent activity against resistant Streptococcus pneumoniae . Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目标是提供式（I）的化合物或其药理学上可接受的盐或溶剂，其中A代表芳基，而R1代表五元或六元单环杂环基，或A代表四至六元单环杂环基，而R1代表芳基或五元或六元单环杂环基；R2代表氢原子或C1-6烷基；R3代表C1-6烷基或C3-6环烷基-C1-4烷基；R4、R5和R6代表氢原子；R7代表C1-6烷基；m为1至3。这些化合物是新型的林可霉素衍生物，对耐药性肺炎链球菌具有强效活性。此外，这些化合物可用作抗微生物剂，对预防或治疗细菌感染性疾病有用。
• 1,2,6-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20150119382A1

  公开（公告）日：2015-04-30

  The present invention relates to compounds of Formula (I), and solvates, hydrates, and pharmaceutically acceptable salts thereof, wherein X 1 , X 1 ′, X 1 ″, R 1 , R 2 and R 3 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

  本发明涉及式（I）化合物及其溶剂合物、水合物和药学上可接受的盐，其中X1、X1'、X1"、R1、R2和R3如本文所定义，其作为FLAP调节剂有用。本发明还涉及包括式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也在本发明范围内。
• SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL]-2-AZABICYCLO [2.2.1]HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2758398B1

  公开（公告）日：2017-08-02